Roche says data shows Cotellic combination therapy effective

October 6, 2015 5:17 AM

20 0

ZURICH Oct 6 Swiss drugmaker Roche said final survival data from a Phase III clinical trial showed the Cotellic drug used in combination with Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer compared to Zelboraf alone.

Ongoing monitoring did not identify any new safety signals. Long-term safety data was expected later this year, it added in a statement on Tuesday. Cotellic was discovered by Exelixis Inc and is being developed by Roche and Exelixis.

Also read: Asian Shares Boosted After Fall on Japan Trade Data

Read more

To category page